Official Title: “Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)”

The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing all cause mortality in patients who have heart failure with preserved systolic function.

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Study Primary Completion Date: July 2011

BACKGROUND:

Heart failure (HF) is a major cause of morbidity and mortality, particularly in older people.

Indeed, it is the most common discharge diagnosis in patients older than 65 years. As the United States population ages, heart failure will continue to grow as a public health concern. Therapeutic trials of heart failure have dealt almost exclusively with patients who have systolic dysfunction. However, there is now an emerging awareness that nearly half of the patients with heart failure have preserved systolic function and that the survival of these patients is adversely affected. This study is a randomized clinical trial of a novel therapeutic approach, specifically the use of an aldosterone antagonist, in treating these patients. While this treatment has been shown to be useful in treating heart failure with reduced systolic function, it has not been studied in patients with preserved systolic function.

Patients with heart failure and preserved systolic function have a poor prognosis. The annual mortality rate is intermediate between the prognosis for those without heart failure and for those with heart failure and reduced systolic function. For instance, Family Health Study participants with heart failure and preserved systolic function had a mortality rate of 9 % compared to 3 % for age- and gender-matched controls. The mortality rate was 19 % compared to 4 % for matched controls in heart failure patients with reduced systolic function heart failure.

As heart failure develops, neurohormones are released that initially improve cardiac output but ultimately contribute to progression of left ventricular dysfunction. The renin-angiotensin-aldosterone system is an important part of this compensatory response.

Aldosterone levels may rise to 20 times normal levels in heart failure and aldosterone contributes to the development of myocardial fibrosis. Spironolactone is a potassium-sparing diuretic that acts on the distal tubule, inhibiting sodium and potassium ion exchange. There are several potential beneficial actions, including prevention of cardiac fibrosis. A recent trial evaluated spironolactone in patients with systolic dysfunction heart failure.

Spironolactone treatment caused a 30% reduction in mortality compared to placebo (p< 0.001).

The improvement resulted from a reduction in all cause mortality. More recently, the Eplerenone Post-Myocardial Infarction (MI) study showed that this aldosterone antagonist significantly reduces mortality despite background treatment with an angiotensin-converting enzyme (ACE) inhibitor and beta-blocker. Advantages of using spironolactone in this study are that it is commercially available, inexpensive, and no longer under patent (therefore this study will not be done by industry). Also, there is a clear physiologic rationale for its use, and the side effect profile is well understood. The study is currently enrolling patients hospitalized with heart failure who have preserved systolic function and who meet clearly defined eligibility criteria that have been selected to make the results widely generalizable to clinical practice.

DESIGN NARRATIVE:

This is a randomized, double-blinded, placebo-controlled trial of aldosterone antagonist therapy (15 mg dose spironolactone or placebo; titrated up to 45 mg/day) in 4,500 adult patients with heart failure and preserved systolic function. Patients will be recruited over two and a half years, treated, and followed for approximately two years. Approximately 150 clinical sites will be subcontracted to the clinical trial coordinating center. Patient visits to a clinical center will occur every four or six months. Data to be collected include demographic and clinical data, including the results of history and physical exams, laboratory and imaging data, repository specimens for special physiology studies, and genetic studies. Additionally, data regarding cost-effectiveness, quality of life, and compliance with assigned treatment will also be collected and assessed. The protocol has been developed.

Enrollment began August 2006.

Intervention(s) in this Clinical Trial

• Drug: Aldosterone Antagonist (spironolactone)
  • Spironolactone is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (tablets). Subjects are on study drug for the duration of the trial.
• Drug: Placebo
  • Placebo of spironolactone

Arms, Groups and Cohorts in this Clinical Trial

• Placebo Comparator: 1
  • Placebo
• Experimental: 2
  • Spironolactone

Primary Measures

• Aborted cardiac arrest
  • Time Frame: Measured at baseline, 1 week, 4 weeks, 8 weeks, 4 months, 8 months, 12 months, and every 6 months thereafter (last visit is at 54 months)
    Safety Issue?: Yes
• Composite of hospitalization for the management of heart failure (i.e., hospitalization for non-fatal MI or non-fatal stroke)
  • Time Frame: Measured at baseline, 1 week, 4 weeks, 8 weeks, 4 months, 8 months, 12 months, and every 6 months thereafter (last visit is at 54 months)
    Safety Issue?: Yes

Secondary Measures

• All cause mortality
  • Time Frame: Measured at baseline, 1 week, 4 weeks, 8 weeks, 4 months, 8 months, 12 months, and every 6 months thereafter (last visit is at 54 months)
    Safety Issue?: Yes
• Composite of cardiovascular mortality or cardiovascular related hospitalization (i.e., hospitalization for non-fatal MI, non-fatal stroke, or the management of heart failure)
  • Time Frame: Measured at baseline, 1 week, 4 weeks, 8 weeks, 4 months, 8 months, 12 months, and every 6 months thereafter (last visit is at 54 months)
    Safety Issue?: Yes
• Hospitalization for the management of heart failure incidence rate
  • Time Frame: Measured at baseline, 1 week, 4 weeks, 8 weeks, 4 months, 8 months, 12 months, and every 6 months thereafter (last visit is at 54 months)
    Safety Issue?: Yes
• Sudden death or aborted cardiac arrest
  • Time Frame: Measured at baseline, 1 week, 4 weeks, 8 weeks, 4 months, 8 months, 12 months, and every 6 months thereafter (last visit is at 54 months)
    Safety Issue?: Yes

INCLUSION CRITERIA:

• Heart failure as defined by at least one of the following symptoms at the time of screening and at least one of the following signs within 12 months of study entry:
• 1. SYMPTOMS:
• 1. Paroxysmal nocturnal dyspnea
• 2. Orthopnea
• 3. Dyspnea on mild or moderate exertion
• 2. SIGNS:
• 1. Any rales post cough
• 2. JVP greater than or equal to 10 cm H2O
• 3. Lower extremity edema
• 4. Chest x-ray demonstrating pleural effusion, pulmonary congestion, or cardiomegaly
• LVEF (ideally obtained by echocardiography, although radionuclide ventriculography and angiography are acceptable) greater than or equal to 45% (per local reading); the ejection fraction must have been obtained within 6 months prior to randomization and after any MI or other event that would affect ejection fraction
• Controlled systolic BP, defined as a target systolic BP less than 140 mm Hg;
• participants with BP up to and including 160 mm Hg are eligible for enrollment if they are on three or more medications to control BP
• Serum potassium less than 5.0 mmol/L prior to randomization
• At least one hospital admission for which heart failure was a major component of the hospitalization some time within the 12 months prior to study entry (transient heart failure in the context of MI does not qualify) OR brain natriuretic peptide (BNP) greater than or equal to 100 pg/ml or N-terminal pro-BNP greater than or equal to 360 pg/ml (not explained by another disease entity) within the 30 days prior to study entry
• Women of child-bearing potential must have a negative serum/urine pregnancy test within 72 hours prior to randomization, must not be lactating, and must agree to use an effective method of contraception during the entire course of study participation
• Willing to comply with scheduled visits

EXCLUSION CRITERIA:

• Severe systemic illness with an expected life expectancy of less than 3 years
• Chronic pulmonary disease requiring home O2, oral steroid therapy, or hospitalization for exacerbation within 12 months of study entry, or significant chronic pulmonary disease in the opinion of the investigator
• Known infiltrative or hypertrophic obstructive cardiomyopathy or known pericardial constriction
• Primary hemodynamically significant uncorrected valvular heart disease, obstructive or regurgitant, or any valvular disease expected to lead to surgery during the trial
• Atrial fibrillation with a resting heart rate greater than 90 bpm
• MI in the past 90 days
• Coronary artery bypass graft surgery in the past 90 days
• Percutaneous coronary intervention in the past 30 days
• Heart transplant recipient
• Currently implanted left ventricular assist device
• Stroke in past 90 days
• Systolic BP less than 160 mm Hg
• Known orthostatic hypotension
• Gastrointestinal disorder that could interfere with study drug absorption
• Use of any aldosterone antagonist or potassium sparing medication in the 7 days prior to study entry
• Known intolerance to aldosterone antagonists
• Current lithium use
• Current participation (including prior 30 days) in any other therapeutic trial
• Any condition that, in the opinion of the investigator, may prevent the participant from adhering to the trial protocol
• History of hyperkalemia (serum potassium greater than or equal to 5.5 mmol/L) in the past 6 months or serum potassium greater than or equal to 5.0 mmol/L within the past 2 weeks
• Severe renal dysfunction, defined as an estimated GFR less than 30 ml/min (per the Modification of Diet in Renal Disease (MDRD) 4-component study equation); participants with serum creatinine greater than or equal to 2.5 mg/dl are also excluded even if their GFR is greater than or equal to 30 ml/min
• Known chronic hepatic disease, defined as AST and ALT levels greater than 3.0 times the upper limit of normal as read at the local lab

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 50 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Overall Clinical Trial Officials and Contacts

Sonja McKinlay, PhD Principal Investigator New England Research Institutes, Inc.  

Overall Contact: Sonja McKinlay, PhD 617-923-7747 TOPCAT@neriscience.com

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00094302

Study ID Number: 160

ClinicalTrials.gov Identifier: NCT00094302

Health Authority: United States: Food and Drug Administration